Raymond James Financial Services Advisors Inc. trimmed its position in Atrion Corporation (NASDAQ:ATRI) by 10.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,532 shares of the medical instruments supplier’s stock after selling 308 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.14% of Atrion Corporation worth $1,629,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ATRI. Janus Henderson Group PLC acquired a new position in shares of Atrion Corporation in the second quarter valued at $13,898,000. Renaissance Technologies LLC grew its position in Atrion Corporation by 46.3% in the second quarter. Renaissance Technologies LLC now owns 58,834 shares of the medical instruments supplier’s stock valued at $37,848,000 after acquiring an additional 18,633 shares during the period. Neuberger Berman Group LLC grew its position in Atrion Corporation by 7.4% in the second quarter. Neuberger Berman Group LLC now owns 82,894 shares of the medical instruments supplier’s stock valued at $53,326,000 after acquiring an additional 5,695 shares during the period. Prudential Financial Inc. grew its position in Atrion Corporation by 583.6% in the second quarter. Prudential Financial Inc. now owns 4,970 shares of the medical instruments supplier’s stock valued at $3,197,000 after acquiring an additional 4,243 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Atrion Corporation by 600.4% in the second quarter. Ameriprise Financial Inc. now owns 3,383 shares of the medical instruments supplier’s stock valued at $2,177,000 after acquiring an additional 2,900 shares during the period. Institutional investors and hedge funds own 59.71% of the company’s stock.

In other news, Chairman Emile A. Battat sold 1,408 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $652.91, for a total transaction of $919,297.28. Following the completion of the transaction, the chairman now owns 148,881 shares of the company’s stock, valued at approximately $97,205,893.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 23.10% of the stock is currently owned by insiders.

Separately, BidaskClub upgraded Atrion Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 29th.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/21/raymond-james-financial-services-advisors-inc-sells-308-shares-of-atrion-corporation-atri.html.

Shares of Atrion Corporation (NASDAQ:ATRI) opened at 675.00 on Friday. The company has a market capitalization of $1.25 billion, a PE ratio of 37.82 and a beta of 0.92. The firm has a 50-day moving average price of $664.19 and a 200-day moving average price of $599.57. Atrion Corporation has a 12 month low of $426.20 and a 12 month high of $694.00.

Atrion Corporation (NASDAQ:ATRI) last announced its quarterly earnings data on Tuesday, August 8th. The medical instruments supplier reported $5.40 earnings per share for the quarter. The firm had revenue of $36.16 million during the quarter. Atrion Corporation had a return on equity of 18.67% and a net margin of 22.75%. On average, equities research analysts predict that Atrion Corporation will post $9.90 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 15th were issued a dividend of $1.20 per share. The ex-dividend date was Thursday, September 14th. This represents a $4.80 dividend on an annualized basis and a dividend yield of 0.71%. This is a boost from Atrion Corporation’s previous quarterly dividend of $1.05. Atrion Corporation’s payout ratio is 26.88%.

Atrion Corporation Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Corporation (NASDAQ:ATRI).

Institutional Ownership by Quarter for Atrion Corporation (NASDAQ:ATRI)

Receive News & Stock Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related stocks with our FREE daily email newsletter.